Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects

Active, not recruiting

Phase 2 Results N/A

Summary of Purpose

The purpose of this study is to demonstrate the safety of the delivery of ALD-401 by intracarotid infusion and to assess efficacy of treatment in subjects who have had unilateral, predominately cortical, ischemic strokes in the middle cerebral artery (MCA). ALD-401 is made from the stroke patient's bone marrow and infused 13-19 days after the stroke.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 14 January 2014.

1 Mar 2011 6 Jan 2011 1 Jul 2014 1 Jan 2015 1 Jan 2014 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Conditions See All

Sponsors

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment

Contacts